<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>
<head>
<title>6 cardiovascular - Class 1 antiarrhythmics</title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<link href="../sgStyles2.css" rel="stylesheet" type="text/css">
</head>

<body>
	<a id="top"></a>
		<div id="text">
<p class="titleSG">Class 1 antiarrhythmics - Sodium channel blockers</p>
<p>Can be subclassified on receptor kinetics - class 1b interact with sodium channels 
  and dissociate again in less than 1 sec, class 1a 1 - 10 secs, class 1c &gt; 
  10 secs. </p>
<p><strong><img src="images/class-1-ap-col.gif" width="300" height="192"></strong></p>
<p><strong>Effects</strong><br>
  Decreased slope of phase four, increased firing threshold (reduced automaticity), 
  increased effective refractory period. The action potential may be either slightly 
  prolonged or slightly shortened. Action potentials triggered by after depolarisations 
  are inhibited. <br>
  Effects on animals will vary according to the heart rate, the tissue and its 
  health (in general, these drugs have a greater effect on diseased tissue). This 
  means that class 1 drugs can have a wide range of effects.</p>
<p class="footerSG">Class 1a antiarrhythmics</p>
<p><strong>Quinidine</strong> is mainly used in horses because it is cheap enough 
  to give horse size doses. It is used in supraventricular arrhythmias especially 
  <a href="cardATachECGs.html">atrial fibrillation</a>.<br>
  Quinidine has a short half life in dogs and cats so is not much use for maintenance. 
  It is poorly tolerated by dogs.</p>
<p><strong>Side effects and toxicity</strong></p>
<blockquote>
  <p>&#8226;anorexia, vomiting, diarrhoea<br>
    &#8226;QRS duration and Q-T intervals are increased - if there is a 50% increase 
    in the QRS then remove drug promptly ie. need to monitor with ECG<br>
    &#8226;ventricular arrhythmias - increase in Purkinje fibre automaticity<br>
    &#8226;sudden death due to <a href="cardVTachECGs.html">ventricular fibrillation</a> 
    is possible</p>
</blockquote>
<p>All these are potentiated by hypokalaemia.</p>
<p><strong>Contraindications</strong><br>
  myasthenia gravis, complete A-V block, intraventricular conduction defects, 
  symptoms of digitalis toxicity<br>
  Care is required in acid-base disorders, hypokalaemia, hypoxia, and renal or 
  liver insufficiency</p>
<p><strong>Interactions</strong><br>
  increases <a href="cardDig.html">digitalis</a> plasma levels - displaces digoxin 
  from skeletal muscle binding and reduces digoxin plasma clearance<br>
  increased chance of arrhythmias with diuretics which induce hypokalaemia, ie 
  frusemide and thiazides.</p>
<p><strong>Procainamide</strong> is effective against <a href="cardVTachECGs.html">ventricular 
  tachyarrhythmias</a> and was used primarily for these but may be effective against 
  <a href="cardATachECGs.html">supraventricular arrhythmias</a> in high doses. 
  It can be given iv or as sustained release tablets (short t<sub>1/2</sub> of 
  2.5 - 4.7 hours therefore require either an iv infusion or sustained release). 
  Side effects are similar to quinidine. Higher concentrations decrease myocardial 
  contractility and produce hypotension. Care in renal disease - reduce dose. 
  No longer available in NZ.</p>
<p class="footerSG">Class 1b antiarrhythmics</p>
<p><strong>Lignocaine</strong> (lidocaine USAN) is used in life threatening ventricular 
  arrhythmias, particularly <a href="cardVTachECGs.html">v. tachycardia and v. 
  premature complexes</a>. Do not use lignocaine with adrenaline - this is only 
  for <a href="../CNSfiles/CNSlocal.html">local anaesthetic</a> use.</p>
<p><strong><a href="../PKsFiles/PKsIndex.html">Pharmacokinetics</a></strong><br>
  <em>Absorption</em> - onset of action after iv injection is within 2 minutes 
  and duration of 10-20 minutes<br>
  <em>Distribution</em> - rapidly redistributed into highly perfused organs - 
  heart failure may decrease the volume of distribution (Vd is about 4.5 l/kg 
  in the dog)<br>
  <em>Metabolism</em> - short half life - 90 - 100 minutes - rapidly metabolised 
  by the liver to active metabolites. This may be prolonged by liver disease or 
  poor hepatic perfusion ie. cardiac disease. If given po, lignocaine is 100% 
  metabolised on the first pass through the liver.<br>
  <em>Elimination</em> - less then 10% of a parenteral dose is excreted unchanged 
  in the urine</p>
<p><strong>Side effects and Toxicity</strong><br>
  CNS effects - drowsiness, emesis, nystagmus, muscle twitching and seizures - 
  can be very severe in the cat<br>
  methaemoglobinuria especially in cats<br>
  Treat by withdrawing drug; may need to use diazepam or barbiturates for <a href="../CNSfiles/CNSantiCon.html">seizure 
  control</a> as well.</p>
<p><strong>Contraindications</strong><br>
  severe SA, AV, or intraventricular heart block<br>
  caution in patients with liver disease, congestive heart failure, shock, hypovolaemia, 
  respiratory depression or hypoxia<br>
  <strong>Tocainide</strong> and <strong>mexilitine</strong> are similar to lignocaine 
  but longer acting and are designed to avoid first pass metabolism so can be 
  given by mouth. They are used sometimes for oral treatment of ventricular tachyarrhythmias. 
  <strong>Phenytoin</strong> is again similar to lignocaine but longer acting 
  with more side effects. Not often used.</p>
<p class="footerSG">Class 1c antiarrhythmics</p>
<p><strong>Flecainide</strong> is the only one available in NZ. Occasionally used 
  in atrial fibrillation and other supraventricular tachycardias.</p>
<blockquote> 
  <p><a href="cardAnArrMech.html">pathogenesis of arrythmias</a><br>
    <a href="cardAntiArr.html">back to antiarrhythmics</a></p>
</blockquote>
<table width="90%" border="0" align="center">
  <tr> 
    <td class="titleSG"><a href="cardIndex.html" class="aTitle">6 Cardiovascular 
      index</a></td>
    <td width="50%" class="titleSG">
<div align="right"><a href="cardHFindex.html" class="aTitle">Heart failure index</a></div></td>
  </tr>
</table>
<br>
<table width="90%" border="0" align="center">
  <tr align="center">
    <td>    <a href="../../indexpharm.html"><img src="../../PharmBut.gif" width="100" height="21" border="0"></a></td>
    <td><a href="../../toxSite/indexTox.html"><img src="../../ToxBut.gif" width="100" height="21" border="0"></a></td>
    <td><a href="../indexSG.html"><img src="../../SGbut.gif" width="100" height="21" border="0"></a></td>
    <td><a href="../../lectureSite/indexLec.html"><img src="../../LecBut.gif" width="100" height="21" border="0"></a></td>
    <td><a href="../../formSite/Aform.html" target="_blank"><img src="../../FormBut.gif" width="100" height="21" border="0"></a></td>
    <td><a href="../../casesSite/indexCases.html"><img src="../../CaseBut.gif" width="100" height="21" border="0"></a></td>
  </tr>
</table>
<br>
<table width="90%" border="0" align="center" cellpadding="2" cellspacing="0">
  <tr bgcolor="#FFFFFF">
    <td width="50%" class="commonname"><img src="../../pharmBits/images/mulogo.gif" width="170" height="25"></td>
    <td width="50%" align="right" class="references"><div align="right">copyright
        Massey University</div>
    </td>
  </tr>
</table>
<p>&nbsp;</p>
</div>
</body>
</html>
